Search

Regeneron Pharmaceuticals Inc

Închisă

SectorSănătate

800.7 -0.61

Rezumat

Modificarea prețului

24h

Curent

Minim

789.59

Maxim

806.15

Indicatori cheie

By Trading Economics

Venit

570M

1.3B

Vânzări

685M

4.3B

P/E

Medie Sector

19.42

57.002

EPS

12.53

Randament dividend

0.46

Marjă de profit

30.226

Angajați

15,410

EBITDA

576M

1.5B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+2.85% upside

Dividende

By Acuity

Randament dividend

Medie Sector

0.46%

2.22%

Următoarele câștiguri

27 oct. 2026

Data viitoare de dividende

31 aug. 2026

Următoarea dată ex-dividende

18 aug. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

13B

83B

Deschiderea anterioară

801.31

Închiderea anterioară

800.7

Sentimentul știrilor

By Acuity

10%

90%

14 / 340 Clasament în Healthcare

Regeneron Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 aug. 2026, 19:16 UTC

News
Social Media

Regeneron Pharmaceuticals is trading higher as social media highlights REGN17235's potential in ongoing clinical trials, supporting strong performance since Wednesday's close.

12 aug. 2026, 23:01 UTC

News

Regeneron Pharmaceuticals faces a securities fraud lawsuit over misleading statements regarding its Phase III Fianlimab-Libtayo Study, contributing to lower after-market trading.

11 aug. 2026, 23:01 UTC

Regeneron Pharmaceuticals shares are modestly higher in after-market hours. No specific company news was identified to explain this movement.

10 aug. 2026, 20:02 UTC

Regeneron Pharmaceuticals Inc shares are higher, supported by broader market strength and reduced expectations for Federal Reserve interest rate hikes following Friday's jobs report.

7 aug. 2026, 22:16 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and unlawful business practices.

6 aug. 2026, 19:26 UTC

News
Social Media

Regeneron Pharmaceuticals faces a potential class action lawsuit over alleged securities fraud, contributing to a decline in shares despite receiving Health Canada approval for Libtayo.

5 aug. 2026, 20:06 UTC

Regeneron Pharmaceuticals is trading higher, reflecting gains since Tuesday, amid a decline in crude oil prices that eases inflationary pressures.

4 aug. 2026, 23:46 UTC

Regeneron Pharmaceuticals is roughly flat in after-market trading, remaining well above its 20-day moving average and near the upper end of its one-month range.

3 aug. 2026, 19:46 UTC

News

Regeneron Pharmaceuticals faces class action lawsuits over alleged securities fraud related to its Phase III Fianlimab-Libtayo Study, contributing to lower share prices.

1 aug. 2026, 00:01 UTC

News

Regeneron Pharmaceuticals shares are lower in after-market hours following a class action lawsuit alleging securities fraud and concerns over a failed clinical trial.

31 iul. 2026, 23:06 UTC

News

Regeneron Pharmaceuticals shares declined in after-market hours following a class action lawsuit alleging securities fraud related to its Phase III study modifications.

30 iul. 2026, 19:49 UTC

Regeneron Pharmaceuticals is trading higher, significantly above its 20-day moving average and near the upper end of its one-month trading range.

29 iul. 2026, 23:16 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining strength above the 20-day moving average despite broader market caution over rising interest rates.

28 iul. 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc is higher in after-hours trading, continuing its positive momentum and remaining above its 20-day moving average. No specific news was identified.

27 iul. 2026, 23:51 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, maintaining momentum with strong cumulative returns and three consecutive higher daily closes.

25 iul. 2026, 00:02 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified.

24 iul. 2026, 20:13 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, remaining near the upper end of their one-month range. No specific news was identified.

23 iul. 2026, 09:56 UTC

Regeneron Pharmaceuticals Inc shares are modestly higher in pre-market trading. No specific company news was identified to explain the price movement.

22 iul. 2026, 23:46 UTC

Regeneron Pharmaceuticals shares are higher in after-hours trading, peaking post-market despite cautious sentiment from rising crude oil prices and geopolitical tensions.

21 iul. 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

17 iul. 2026, 19:26 UTC

Social Media
News

Regeneron Pharmaceuticals faces a class action lawsuit from Levi & Korsinsky, LLP, contributing to ongoing declines in the stock amid market volatility.

16 iul. 2026, 20:03 UTC

Regeneron Pharmaceuticals is trading higher, supported by gains in the Biotechnology sub-sector amid a strong broader market performance today.

15 iul. 2026, 19:16 UTC

Regeneron Pharmaceuticals Inc shares are higher Wednesday, recovering from an earlier dip and remaining above the 20-day moving average. No specific news was identified.

13 iul. 2026, 19:26 UTC

Regeneron Pharmaceuticals shares are lower today amid broader market declines driven by rising oil prices and geopolitical tensions. No specific company news was identified.

11 iul. 2026, 00:01 UTC

Regeneron Pharmaceuticals shares are higher in after-market trading, reflecting a notable gain near the upper end of its one-month trading range.

10 iul. 2026, 19:26 UTC

Correlated Moves

Regeneron Pharmaceuticals Inc shares declined amid broader biotechnology sector pressures and geopolitical tensions, despite earlier reaching a session high before pulling back.

9 iul. 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours following a weak trading session, despite a report showing a decrease in initial jobless claims.

8 iul. 2026, 19:53 UTC

News

Regeneron Pharmaceuticals shares are lower, pressured by declines in the Biotechnology sector and a reduced price target of $730 from Morgan Stanley.

7 iul. 2026, 23:06 UTC

Regeneron Pharmaceuticals Inc shares are higher in after-market trading, supported by stable performance and positioning above the 20-day moving average.

6 iul. 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc shares are lower in after-market hours, with no specific news identified to explain the decline amid mixed market sentiment.

Comparație

Modificare preț

Regeneron Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

2.85% sus

Prognoză pe 12 luni

Medie 828.95 USD  2.85%

Maxim 1,030 USD

Minim 641 USD

În baza a 21 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRegeneron Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

21 ratings

14

Cumpărare

7

Păstrare

0

Vânzare

Sentiment

By Acuity

14 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
help-icon Live chat